The China Union-backed drug contract manufacturer has raised the funding approximately a year and a half after a $60m series A.

Joinn Biologics, a US-based subsidiary of China-headquartered contract manufacturing organisation Joinn Laboratories, has completed a $150m series B round, Lei News reported today.

Alternative asset manager Citic Private Equity led the round, which included Green Pine Capital Partners, Hongtai Aplus, HT Capital, Huagai Capital and Yingke PE.

Joinn Biologics was formed in 2018 and provides a contract development and production system for biopharmaceutical drug developers.

The cash will go towards building research and development and manufacturing hubs in Chinese cities…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn